Cargando…

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma

Galectin-9 (Gal-9) expression can be negatively or positively associated with cancer patient prognosis, depending on the cancer type. However, the nature of this relationship remains unclear in multiple myeloma. Therefore, we evaluated the prognostic value of Gal-9 and its relationship with the expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Byung-Hyun, Park, Yong, Kim, JI-Hea, Kang, Ka-Won, Lee, Seung-Jin, Kim, Seok Jin, Kim, Byung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238373/ https://www.ncbi.nlm.nih.gov/pubmed/34195077 http://dx.doi.org/10.3389/fonc.2021.669817

Ejemplares similares

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022)

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Prognostic Value and Biological Function of Galectins in Malignant Glioma
por: Zhu, Hongtao, et al.
Publicado: (2022)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

Tumor microbiome analysis provides prognostic value for patients with stage III colorectal cancer
por: Kim, Jae Hyun, et al.
Publicado: (2023)

Prognostic Value of Postoperative CEA Clearance in Rectal Cancer Patients with High Preoperative CEA Levels
por: Kim, Jeong Yeon, et al.
Publicado: (2009)

Galectin-8 and -9 as prognostic factors for cervical cancer
por: Beyer, Susanne, et al.
Publicado: (2022)

Supporting data on enhanced reprogramming of human CD34+ hematopoietic stem cells to induced pluripotent stem cells using human placenta-derived cell conditioned medium
por: Lee, Seung-Jin, et al.
Publicado: (2020)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Meta-Analysis on the Neutrophil-Lymphocyte Ratio in Rectal Cancer Treated With Preoperative Chemoradiotherapy: Prognostic Value of Pre- and Post-Chemoradiotherapy Neutrophil-Lymphocyte Ratio
por: Lee, Soo Jin, et al.
Publicado: (2022)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
por: Lee, Suk Jun, et al.
Publicado: (2023)

Prognostic Significance of Galectin-1 but Not Galectin-3 in Patients With Lung Adenocarcinoma After Radiation Therapy
por: Huang, Chun-Chieh, et al.
Publicado: (2022)

Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients
por: Lee, Byung min, et al.
Publicado: (2020)

Spatial and Temporal Expression, and Statin Responsiveness of Galectin-1 and Galectin-3 in Murine Atherosclerosis
por: Lee, Yong-Jin, et al.
Publicado: (2013)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization
por: Kang, Ka-Won, et al.
Publicado: (2020)

Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma
por: Kim, Nah Ihm, et al.
Publicado: (2020)

In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
por: Kim, Jin Ju, et al.
Publicado: (2023)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
por: Liu, Xiaofeng, et al.
Publicado: (2019)

Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer
por: Ryu, Ji-Won, et al.
Publicado: (2023)

Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
por: Kim, Hyung Suk, et al.
Publicado: (2020)

Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma
por: Liu, Xiao-Ping, et al.
Publicado: (2019)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea
por: Lee, Jun-Hee, et al.
Publicado: (2021)

GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer
por: Kim, Tae Hyun, et al.
Publicado: (2023)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation
por: Park, Yong-Jin, et al.
Publicado: (2021)

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)
por: Kim, Ji-Hea, et al.
Publicado: (2023)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
por: Song, Ga-Young, et al.
Publicado: (2023)

Urinary C5b-9 as a Prognostic Marker in IgA Nephropathy
por: Yu, Byung Chul, et al.
Publicado: (2022)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

Prognostic value and multifaceted roles of tetraspanin CD9 in cancer
por: Ondruššek, Róbert, et al.
Publicado: (2023)

The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
por: Kang, Ka-Won, et al.
Publicado: (2021)

Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study
por: Choi, Joon Young, et al.
Publicado: (2023)

Prognostic Value of Baseline (18)F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study
por: Moon, Seung Hwan, et al.
Publicado: (2018)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aemvcdukqmgdkpjovqimdv4fks